移植非適応での多発性骨髄腫に対するRVD lite(A Phase 2 Study of Modified Lenalidomide, Bortezomib and Dexamethasone in Transplant-Ineligible Multiple Myeloma ) - はくいのてんしちゃん論文編
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Treating Frail and Transplant-Ineligible Patients With MM
SWOG - S2209- VRD-Lite Vs DRd-R Vs DRd-DR - Multiple Myeloma Clinical Trials
VRd Lite 療法
Cancers | Free Full-Text | Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Final Thoughts on Case Study and Treating Multiple Myeloma
Cancers | Free Full-Text | 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple My
(PDF) Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis | SpringerLink
How I manage frontline transplant-ineligible multiple myeloma
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
Multiple Myeloma Treatment Options | First Line Therapy
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
Frontline Therapy in Multiple Myeloma
Multiple Myeloma Tumor Board: Maintenance, Consolidation, and Continuous Therapy (Transcript)
Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice
Current approaches to management of newly diagnosed multiple myeloma - Goel - 2022 - American Journal of Hematology - Wiley Online Library
Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients | Future Oncology
Induction Therapy for Newly Diagnosed Multiple Myeloma
Managing A Case of Newly-Diagnosed Transplant-Ineligible MM
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review - McCaughan - 2022 - British Journal of Haematology - Wiley Online Library
VA Committee
